Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions

Table 4 Clinical Outcome of study patients during in-hospital and 30-day follow-up based on MAGE levels

MAGE (mmol/L)		<2.37	2.37-3.65	>3.65	P
Subject number (n)	237	80	78	79	NA
Composite MACE	35 (14.8)	6 (7.5)	11 (14.1)	18 (22.8)	0.025
Cardiac death	4 (1.7)	1 (1.3)	1 (1.3)	2 (2.5)	0.775
Reinfarction	3 (1.3)	0 (0)	1 (1.3)	2 (2.5)	0.361
Repeated TVR	3 (1.3)	0 (0)	1 (1.3)	2 (2.5)	0.361
Recurrent angina	15 (6.3)	3 (3.8)	5 (6.4)	7 (8.9)	0.416
Malignant arrhythmia	10 (4.2)	2 (2.5)	3 (3.8)	5 (6.3)	0.477
Non-cardiac death	1 (0.4)	0 (0)	1 (1.3)	0 (0)	0.359
Non-IRA revascularization	53 (22.4)	12 (15)	16 (21)	25 (32)	0.037

Data given as mean ± SD or n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.